giant cell tumor of bone/fatigue

链接已保存到剪贴板

文章临床试验专利权

选择排序类型

2 结果

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial.

只有注册用户可以翻译文章

登陆注册

Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven.To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with surgically unsalvageable giant cell

Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.

只有注册用户可以翻译文章

登陆注册

OBJECTIVE Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment; however, recurrence remains a problem. Receptor activator of nuclear factor kappa B (RANKL) is responsible for the formation of osteoclastic cells. Discovery of RANKL

加入我们的脸书专页

Herbal & Natural Medicine

科学支持的最完整的草药数据库

支持55种语言
科学支持的草药疗法
通过图像识别草药
交互式GPS地图-在位置标记草药（即将推出）
阅读与您的搜索相关的科学出版物
通过药效搜索药草
组织您的兴趣并及时了解新闻研究，临床试验和专利

输入症状或疾病，并阅读可能有用的草药，输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究